Phytocannabinoids-Evaluation of their therapeutic role in neuroinflammation

Sharon Smith , Taurri Spurgeon , Ruarri Spurgeon , David Heal

Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (4) : 325 -348.

PDF (3457KB)
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (4) :325 -348. DOI: 10.37349/ent.2024.00087
Review
research-article
Phytocannabinoids-Evaluation of their therapeutic role in neuroinflammation
Author information +
History +
PDF (3457KB)

Abstract

Neuroinflammation can be caused by disease, aging, infection, brain injury, toxicity, or stress. It is a contributory factor in the neuropathology of serious conditions that include multiple sclerosis (MS), Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and autoimmune encephalomyelitis (EAE). The neuroinflammatory response involves the activation of microglia, astrocytes, the endothelial cells of the blood-brain barrier, and peripherally-derived immune cells. The endocannabinoid system is composed of the natural cannabinoids, anandamide and 2-arachidonoyl glycerol (2-AG), enzymes regulating their synthesis/catabolism, and the cannabinoid CB1 and CB2 receptors. It regulates multiple systems in the body including inflammation and endocannabinoid system dysregulation is involved in numerous inflammatory conditions. The Cannabis sativa plant produces over 100 phytocannabinoids, some of which interact with the endocannabinoid system. The major phytocannabinoids are delta-9-tetrahydrocannabinol (delta-9-THC), cannabidiol (CBD), and cannabigerol (CBG). Compelling evidence is emerging that many phytocannabinoids have anti-inflammatory and antioxidant properties. Phytocannabinoids including delta-9-THC, CBD, and CBG bind to a wide variety of targets in the endocannabinoid and/or other systems, which probably accounts for their diversity of effects in non-clinical and clinical studies. The benefits of certain phytocannabinoids have been proven by regulatory approval for medical use of CBD (Epidiolex®), chemically synthesized delta-9-THC (Marinol® and Syndros®) and 1:1 delta-9-THC/CBD (Sativex®). Furthermore, the widely recognized therapeutic properties of Cannabis have been a key driver in legalizing the medical use of Cannabis in 38 USA states. In this review, the potential of phytocannabinoids as effective treatments in neuroinflammatory disorders is discussed based on a critical evaluation of the non-clinical and clinical evidence. We focused on delta-9-THC, CBD, and CBG because they are the most abundant phytocannabinoids in Cannabis sativa and a substantial body of scientific data exists to describe their respective pharmacological mechanisms.

Keywords

Phytocannabinoids / delta-9-tetrahydrocannabinol / cannabidiol / cannabigerol / neuroinflammation / antioxidant activity / neuroprotection

Cite this article

Download citation ▾
Sharon Smith, Taurri Spurgeon, Ruarri Spurgeon, David Heal. Phytocannabinoids-Evaluation of their therapeutic role in neuroinflammation. Exploration of Neuroprotective Therapy, 2024, 4 (4) : 325-348 DOI:10.37349/ent.2024.00087

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol. 2009; 19: 392-8.

[2]

Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem. 2007; 20: 947-56.

[3]

Linker RA, Mäurer M, Gaupp S, Martini R, Holtmann B, Giess R, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med. 2002; 8: 620-4.

[4]

Dunn AJ, Swiergiel AH, Zhang H, Quan N. Reduced ingestion of sweetened milk induced by interleukin-1 and lipopolysaccharide is associated with induction of cyclooxygenase-2 in brain endothelia. Neuroimmunomodulation. 2006; 13: 96-104.

[5]

Norden DM, Trojanowski PJ, Villanueva E, Navarro E, Godbout JP. Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia. 2016; 64: 300-16.

[6]

Matei D, Trofin D, Iordan DA, Onu I, Condurache I, Ionite C, et al. The Endocannabinoid System and Physical Exercise. Int J Mol Sci. 2023; 24: 1989.

[7]

Behl T, Makkar R, Sehgal A, Singh S, Makeen HA, Albratty M, et al. Exploration of multiverse activities of endocannabinoids in biological systems. Int J Mol Sci. 2022; 23: 573.

[8]

Rathod SS, Agrawal YO. Phytocannabinoids as potential multitargeting neuroprotectants in Alzheimer’s disease. Curr Drug Res Revs. 2024; 16: 94-110.

[9]

Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009; 11: e3.

[10]

Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013; 64: 21-47.

[11]

Boorman E, Zajkowska Z, Ahmed R, Pariante CM, Zunszain PA. Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? Psychopharmacology (Berl). 2016; 233: 1591-604.

[12]

Al-Khazaleh AK, Zhou X, Bhuyan DJ, Münch GW, Al-Dalabeeh EA, Jaye K, et al. The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects. Molecules. 2024; 29: 410.

[13]

Ligresti A, de Petrocellis L, di Marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev. 2016; 96: 1593-659.

[14]

Stasiłowicz A, Tomala A, Podolak I, Cielecka-Piontek J. Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment. Int J Mol Sci. 2021; 22: 778.

[15]

de Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011; 163: 1479-94.

[16]

Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007; 152: 1092-101.

[17]

Naya NM, Kelly J, Corna G, Golino M, Polizio AH, Abbate A, et al. An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects. Molecules. 2024;29:473.

[18]

Zagzoog A, Mohamed KA, Kim HJJ, Kim ED, Frank CS, Black T, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa . Sci Rep. 2020; 10: 20405.

[19]

Stone NL, Murphy AJ, England TJ, O’Sullivan SE. A systematic review of minor phytocannabinoids with promising neuroprotective potential. Br J Pharmacol. 2020; 177: 4330-52.

[20]

Rao R, Nagarkatti PS, Nagarkatti M. Δ9 Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells. Br J Pharmacol. 2015; 172: 1792-806.

[21]

Sido JM, Jackson AR, Nagarkatti PS, Nagarkatti M. Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. J Mol Med (Berl). 2016; 94: 1039-51.

[22]

Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A. 2006; 103: 7895-900.

[23]

Karuppagounder V, Chung J, Abdeen A, Thompson A, Bouboukas A, Pinamont WJ, et al. Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis. Cannabis Cannabinoid Res. 2023; 8: 1030-44.

[24]

Formukong EA, Evans AT, Evans FJ. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation. 1988; 12: 361-71.

[25]

Deiana S. Chapter 99-Potential Medical Uses of Cannabigerol: A brief overview. In: Preedy VR, editor. Handbook of Cannabis and Related Pathologies. San Diego: Academic Press; 2017. pp. 958-67.

[26]

Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016; 20: 936-48.

[27]

Kolbe MR, Hohmann T, Hohmann U, Ghadban C, Mackie K, Zöller C, et al. THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner. Cancers (Basel). 2021; 13: 1064.

[28]

Lanuti M, Talamonti E, Maccarrone M, Chiurchiù V. Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages. PLoS One. 2015; 10: e0126839.

[29]

Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, et al. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem. 2012; 287: 91-104.

[30]

Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 2008; 139: 225-36.

[31]

Yimam M, O’Neal A, Horm T, Jiao P, Hong M, Rossiter S, et al. Antinociceptive and Anti-Inflammatory Properties of Cannabidiol Alone and in Combination with Standardized Bioflavonoid Composition. J Med Food. 2021; 24: 960-7.

[32]

DeLong GT, Wolf CE, Poklis A, Lichtman AH. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ9-tetrahydrocannabinol. Drug Alcohol Depend. 2010; 112: 126-33.

[33]

Turner CE, Elsohly MA. Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol. 1981; 21: 283S-91S.

[34]

Davis WM, Hatoum NS. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen Pharmacol. 1983; 14: 247-52.

[35]

Mammana S, Cavalli E, Gugliandolo A, Silvestro S, Pollastro F, Bramanti P, et al. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol. Medicina (Kaunas). 2019; 55: 747.

[36]

Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease. Mol Neurobiol. 2019; 56: 7719-30.

[37]

Chen L, Sun Y, Li J, Liu S, Ding H, Wang G, et al. Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer’s Disease Neurodegeneration. Cells. 2023; 12: 2672.

[38]

Liang Z, Soriano-Castell D, Kepchia D, Duggan BM, Currais A, Schubert D, et al. Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors. Free Radic Biol Med. 2022; 180: 33-51.

[39]

Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s Disease. Mol Pharmacol. 2011; 79: 964-73.

[40]

Silvestro S, Schepici G, Bramanti P, Mazzon E. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease. Molecules. 2020; 25: 5186.

[41]

Patricio F, Morales Dávila E, Patricio-Martínez A, Arana Del Carmen N, Martínez I, Aguilera J, et al. Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats. Front Pharmacol. 2022; 13: 945836.

[42]

Giuliano C, Francavilla M, Ongari G, Petese A, Ghezzi C, Rossini N, et al. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease. Int J Mol Sci. 2021; 22: 8920.

[43]

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, et al. GPR55: A therapeutic target for Parkinson’s disease? Neuropharmacology. 2017; 125: 319-32.

[44]

Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain. 2011; 134: 119-36.

[45]

Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice. Neuroscience. 2010; 170: 324-36.

[46]

Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015; 12: 185-99.

[47]

Al-Ghezi ZZ, Busbee PB, Alghetaa H, Nagarkatti PS, Nagarkatti M. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav Immun. 2019; 82: 25-35.

[48]

Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis. 2010; 37: 434-40.

[49]

Khaksar S, Bigdeli MR. Correlation Between Cannabidiol-Induced Reduction of Infarct Volume and Inflammatory Factors Expression in Ischemic Stroke Model. Basic Clin Neurosci. 2017; 8: 139-46.

[50]

Bhatt D, Hazari A, Yamakawa GR, Salberg S, Sgro M, Shultz SR, et al. Investigating the cumulative effects of Δ9-tetrahydrocannabinol and repetitive mild traumatic brain injury on adolescent rats. Brain Commun. 2020; 2: fcaa042.

[51]

Fehily B, Bartlett CA, Lydiard S, Archer M, Milbourn H, Majimbi M, et al. Differential responses to increasing numbers of mild traumatic brain injury in a rodent closed-head injury model. J Neurochem. 2019; 149: 660-78.

[52]

Madathil SK, Wilfred BS, Urankar SE, Yang W, Leung LY, Gilsdorf JS, et al. Early Microglial Activation Following Closed-Head Concussive Injury Is Dominated by Pro-Inflammatory M-1 Type. Front Neurol. 2018; 9: 964.

[53]

Black T, Zagoog A, Roebuck AJ, Greba Q, Neary JP, Howland JG, et al. Sex-specific differences in rotarod performance and type 1 cannabinoid receptor levels in a rat model of traumatic brain injury treated with Δ9-tetrahydrocannabinol. BioRxiv 487790 [Preprint]. 2022 [cited 2024 Mar 18]. Available from: https://www.biorxiv.org/content/10.1101/2022.04.11.487790v1

[54]

Belardo C, Iannotta M, Boccella S, Rubino RC, Ricciardi F, Infantino R, et al. Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury. Front Pharmacol. 2019; 10: 352.

[55]

Jiang H, Li H, Cao Y, Zhang R, Zhou L, Zhou Y, et al. Effects of cannabinoid (CBD) on blood brain barrier permeability after brain injury in rats. Brain Res. 2021; 1768: 147586.

[56]

Sativex Oromucosal Spray [Internet]. Datapharm; [cited 2024 Mar 5]. Available from: https://www.medicines.org.uk/emc/product/602

[57]

Assessment report [Internet]. Amsterdam: European Medicines Agency; c2019 [cited 2024 Mar 6]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/epidyolex-epar-public-assessment-report_en.pdf

[58]

MARINOL (dronabinol) capsules, for oral use, CIII [Internet]. U.S. Food and Drug Administration; [cited 2024 Mar 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf

[59]

LABEL: SYNDROS-dronabinol solution [Internet]. National Institutes of Health and National Library of Medicine; [cited 2024 Mar 5]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7801c70-995d-46a2-91ee-141ef427c6b5

[60]

LABEL: CESAMET-nabilone capsule [Internet]. National Institutes of Health and National Library of Medicine; [cited 2024 Mar 4]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83c7ac15-ece9-47de-b83c-d575544fa449

[61]

Justice Department submits proposed regulation to reschedule marijuana [Internet]. Washington: Office of Public Affairs US Department of Justice; [cited 2024 Mar 5]. Available from: https://www.justice.gov/opa/pr/justice-department-submits-proposed-regulation-reschedule-marijuana

[62]

Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502-17.

[63]

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012; 8: 647-56.

[64]

Manjaly Z, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019; 90: 642-51.

[65]

Klotz L, Antel J, Kuhlmann T. Inflammation in multiple sclerosis: consequences for remyelination and disease progression. Nat Rev Neurol. 2023; 19: 305-20.

[66]

Sibaev A, Yüce B, Kemmer M, van Nassauw L, Broedl U, Allescher HD, et al. Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G119-28.

[67]

Sibaev A, Yuece B, Allescher HD, Saur D, Storr M, Kurjak M. The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. Pharmacol Rep. 2014; 66: 256-63.

[68]

Oliviero A, Arevalo-Martin A, Rotondi M, García-Ovejero D, Mordillo-Mateos L, Lozano-Sicilia A, et al. CB1 receptor antagonism/inverse agonism increases motor system excitability in humans. Eur Neuropsychopharmacol. 2012; 22: 27-35.

[69]

Maramai S, Brindisi M. Targeting Endocannabinoid Metabolism: an Arrow with Multiple Tips Against Multiple Sclerosis. ChemMedChem. 2020; 15: 1985-2003.

[70]

De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One. 2011; 6: e28159.

[71]

Harvey BS, Sia TC, Wattchow DA, Smid SD. Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine. 2014; 65: 236-44.

[72]

Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004; 10: 417-24.

[73]

Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003; 17: 21-9.

[74]

Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004; 10: 434-41.

[75]

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al.; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003; 362: 1517-26.

[76]

Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005; 76: 1664-9.

[77]

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG ; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012; 83: 1125-32.

[78]

Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004; 62: 1105-9.

[79]

Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006; 17: 636-41.

[80]

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012; 184: 1143-50.

[81]

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65: 812-9.

[82]

Russo M, Naro A, Leo A, Sessa E, D’Aleo G, Bramanti P, et al. Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis. Pain Med. 2016; 17: 1145-54.

[83]

Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009; 32: 41-7.

[84]

Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004; 329: 253.

[85]

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007; 133: 210-20.

[86]

Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010; 33: 128-30.

[87]

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006; 45: 50-2.

[88]

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010; 182: E694-701.

[89]

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013; 14: 136-48.

[90]

Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J Pain. 2015; 16: 616-27.

[91]

Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008; 109: 101-10.

[92]

Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2020; 21: 390-402.

[93]

Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022; 163: 1206-14.

[94]

Bawa Z, Lewis D, Gavin PD, Libinaki R, Joubran L, El-Tamimy M, et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Sci Rep. 2024; 14: 11792.

[95]

Benito C, Núñez E, Pazos MR, Tolón RM, Romero J. The endocannabinoid system and Alzheimer’s Disease. Mol Neurobiol. 2007; 36: 75-81.

[96]

Ramírez BG, Blázquez C, Pulgar TGd, Guzmán M, de Ceballos ML. Prevention of Alzheimer’s Disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005; 25: 1904-13.

[97]

Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s Disease brains. J Neurosci. 2003; 23: 11136-41.

[98]

Solas M, Francis PT, Franco R, Ramirez MJ. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s Disease patients. Neurobiol Aging. 2013; 34: 805-8.

[99]

Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009; 1283: 148-54.

[100]

Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, et al. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer’s Disease. Am J Geriatr Psychiatry. 2019; 27: 1161-73.

[101]

Charernboon T, Lerthattasilp T, Supasitthumrong T. Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials. Clin Gerontol. 2021; 44: 16-24.

[102]

van den Elsen GAH, Ahmed AIA, Verkes RJ, Feuth T, van der Marck MA, Olde Rikkert MGM. Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial. Am J Geriatr Psychiatry. 2015; 23: 1214-24.

[103]

van den Elsen GA, Ahmed AI, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. 2015; 84: 2338-46.

[104]

Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s Disease. Int J Geriatr Psychiat. 1997; 12: 913-9.

[105]

Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006; 185: 524-8.

[106]

Jung K, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, et al. An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer’s Disease. Neurobiol Aging. 2012; 33: 1522-32.

[107]

Hua DY, Hindocha C, Baio G, Lees R, Shaban N, Morgan CJ, et al. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder. Transl Psychiatry. 2023; 13: 131.

[108]

Akinyemi E, Randhawa G, Longoria V, Zeine R. Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review. J Pharm Pharm Sci. 2020; 23: 389-95.

[109]

Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991; 40: 701-8.

[110]

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014; 28: 1088-98.

[111]

Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009; 23: 979-83.

[112]

Leehey MA, Liu Y, Hart F, Epstein C, Cook M, Sillau S, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. Cannabis Cannabinoid Res. 2020; 5: 326-36.

[113]

Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 2002; 30: 548-54.

[114]

Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006; 5: 38-45.

[115]

Varshneya NB, Taylor CL, Schutzer WE, Kozell LB, Schmachtenberg JL, Eshleman AJ, et al. Binding Affinity and Functional Activity of 24 Emerging Cannabinoids at the CB1 Receptor and Safety-Related Targets. College on Problems of Drug Dependence. CPDD 2024: Proceedings of the College on Problems of Drug Dependence (CPDD) 86th Annual Scientific Meeting; 2024 Jun 15-19; Montreal, Canada. Poster M38.

PDF (3457KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉